Using specific ligands that can discriminate between SR-BP and sigma2, sigma2 receptors were found to be overexpressed in tumour cells as compared with their normal counterparts, including breast, neural, lung, prostate and melanoma tumours (Vilner et al, 1995). Here, SIGMAR1 is linked to neoplasm.